Cost Effectiveness of Infant Vaccination for Rotavirus in Canada | Zendy

Doug Coyle | Zendy; Kathryn Coyle | Zendy; Julie A. Bettinger | Zendy; Scott A. Halperin | Zendy; Wendy Vaudry | Zendy; David W. Scheifele | Zendy; Nicole Le Saux | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Cost Effectiveness of Infant Vaccination for Rotavirus in Canada

Author(s) -

Doug Coyle,

Kathryn Coyle,

Julie A. Bettinger,

Scott A. Halperin,

Wendy Vaudry,

David W. Scheifele,

Nicole Le Saux

Publication year - 2012

Publication title -

canadian journal of infectious diseases and medical microbiology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.634

H-Index - 38

eISSN - 1918-1493

pISSN - 1712-9532

DOI - 10.1155/2012/327054

Subject(s) - medicine , vaccination , rotavirus , emergency department , cost effectiveness , cost effectiveness analysis , rotavirus vaccine , pediatrics , health care , immunization , environmental health , immunology , nursing , political science , risk analysis (engineering) , virus , antigen , law

Rotavirus is the main cause of gastroenteritis in Canadian children younger than five years of age, resulting in significant morbidity and cost. The present study provides evidence on the cost effectiveness of two alternative rotavirus vaccinations (RotaTeq [Merck Frosst Canada Ltd, Canada] and Rotarix [GlaxoSmithKline, Canada]) available in Canada.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research